Exposure to dipeptidyl-peptidase 4 inhibitors and the risk of pneumonia among people with type 2 diabetes: Retrospective cohort study and meta-analysis.
Mario Luca MorieriBenedetta Maria BonoraEnrico LongatoBarbara Di CamiloGiovanni SparacinoLara TramontanAngelo AvogaroGian Poalo FadiniPublished in: Diabetes, obesity & metabolism (2020)
The use of DPP-4 inhibitors can be considered as safe with regard to the risk of pneumonia.
Keyphrases